Clinical trials: Primary Axillary Hyperhidrosis
Primary Axillary Hyperhidrosis
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis
The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions.
- Trial name
- NCT04159610
- Testing
- WO3970, Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Primary Axillary Hyperhidrosis
Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis
The aim of this study is to evaluate the safety, tolerability and systemic exposure (in a subset of patients) of topical administration of 1% GPB in adolescents with severe primary axillary hyperhidrosis.
- Trial name
- NCT05863104
- Testing
- Glycopyrronium Bromide (GPB) Cream
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Primary Axillary Hyperhidrosis
Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
The Sahara Study is a study to evaluate the safety and effectiveness of the N-SWEAT Patch for use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis.
- Trial name
- NCT04599907
- Testing
- Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Candesant Biomedical, Inc.
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03627468
- Testing
- Sofpironium Bromide Gel, 5%, Sofpironium Bromide Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.
The aim of this study is to investigate the efficacy and safety of 1% GPB cream after 4 weeks of treatment compared with placebo with a sufficient number of patients to obtain statistically significant results, and to assess the…
- Trial name
- NCT03658616
- Testing
- WO3970
- Where
- Germany
- Volunteers
- 518 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03785587
- Testing
- Sofpironium Bromide Gel, 15%
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
Fractionated Microneedle Radiofrequency for Treatment of Primary Axillary Hyperhidrosis
Twenty patients with PAH had 1 session of Fractionated microneedle radiofrequency treatment. Clinical improvement was evaluated using a Hyperhidrosis Disease Severity Scale (HDSS) and photographs were taken using the…
- Trial name
- NCT02823340
- Testing
- Fractional microneedle RF(United, Peninsula Medical, China)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xijing Hospital
Primary Axillary Hyperhidrosis
Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis
The aim of the study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of escalating concentrations of GPB in subjects with axillary hyperhidrosis.
- Trial name
- NCT03037788
- Testing
- WO3979, WO3970, WO3992
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Primary Axillary Hyperhidrosis
Ulthera® System for Treating Axillary Hyperhidrosis
Up to 20 enrolled subjects will be treated. Subjects will receive two Ulthera® treatments on the axillas provided 30 days apart. Follow-up visits will occur at 7, 30, 90 and 180 days following the last treatment.
- Trial name
- NCT02286765
- Testing
- Ulthera System treatment
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis
This is a prospective, multi-center, randomized, double-blinded study. Subjects enrolled will be randomly assigned to receive either active treatments for axillary hyperhidrosis with the Ulthera System in both axillas, or sham…
- Trial name
- NCT01722461
- Testing
- Ulthera System
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
Fractional Micro-Needle Radiofrequency and I Botulinum Toxin A for Primary Axillary Hyperhidrosis
Because of the limiting data about an efficacy and safety of fractional radiofrequency for the treatment of hyperhidrosis, this study aim to compare clinical efficacy by Hyperhidrosis Disease Severity Score (HDSS) between…
- Trial name
- NCT03054480
- Testing
- Fractional Micro-Needle Radiofrequency, Botulinum toxin type A
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mae Fah Luang University Hospital
Primary Axillary Hyperhidrosis
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis
The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT01799824
- Testing
- ANT-1403
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- Anterios Inc.